Australia markets open in 6 minutes

PMV Pharmaceuticals, Inc. (PMVP)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.6000+0.0600 (+3.90%)
At close: 04:00PM EST
1.6000 0.00 (0.00%)
After hours: 05:20PM EST
Full screen
Loading interactive chart…
  • GlobeNewswire

    PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway

    Prioritization of PC14586 development and focused discovery research efforts results in a workforce reduction of approximately 30%Unaudited cash, cash equivalents, and marketable securities totaling approximately $229 million as of December 31, 2023, combined with cost savings from workforce reduction, is expected to extend cash runway to end of 2026PC14586 registrational Phase 2 clinical trial remains on track to initiate in 1Q24 PRINCETON, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceut

  • GlobeNewswire

    PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development

    PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs)Michael Carulli promoted to Chief Financial OfficerRobert Ticktin, General Counsel, will expand responsibilities to include management of OperationsTim Smith, Senior Vice President, Head of Corporate Development, will expand responsibilities to include Investor RelationsPC14586 registrational Phase 2 clinical tr

  • GlobeNewswire

    PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights

    Updated data from Phase 1 PYNNACLE clinical trial of PC14586 presented at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics demonstrated responses across multiple tumor types with median duration of response of seven monthsAn overall response rate of 38% observed at the recommended Phase 2 dose of 2000 mg daily for the intended Phase 2 population of TP53 Y220C and KRAS wild-type patientsRegistrational Phase 2 clinical trial expected to initiate in Q1 2024O